Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis
Asian Pacific Journal of Allergy and Immunology · 2026
DOI: 10.12932/ap-151025-2164 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2026. Verfasst von Yulin Geng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Eosinophilic asthma is a severe phenotype in pediatrics, often refractory to conventional therapy. Biologic agents targeting Type 2 inflammatory pathway are increasingly used in children and adolescents. OBJECTIVE: To evaluate the efficacy and safety of omalizumab, mepolizumab, benralizumab, and dupilumab in pediatric eosinophilic asthma. METHODS: We systematically searched eight databases to March 31, 2025 (PROSPERO: CRD420251017602). Eligible studies were randomized controlled or controlled observational trials in patients 1≤8 years. Outcomes included lung function, asthma control, quality of life (QoL), and adverse events (AEs). RESULTS: Twenty-two studies (n = 2,468) were included. Biologics significantly improved predicted FEV1 (SMD = 0.97, 95%CI: 0.38-1.57), asthma control also improved (SMD = 2.84, 95%CI: 1.40-4.28), as did quality of life (SMD = 1.72, 95%CI: 0.39-3.05). Overall AEs were more frequent (OR 1.48, 95%CI 1.22-1.81), but serious AEs were rare and not increased. Evidence was strongest for omalizumab; data for other biologics remain limited. CONCLUSIONS: Biologic therapies are associated with improvements in clinical outcomes in children and adolescents with eosinophilic asthma, with an increased incidence of predominantly mild adverse events. However, the current evidence is largely driven by studies of omalizumab, and data for other biologics remain limited in pediatric populations. Further long-term and comparative studies are warranted to better define the efficacy and safety profiles of individual biologic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Geng, Y., & Xu, J. (2026). Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-151025-2164
Vancouver
Geng Y, Xu J. Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis. Asian Pacific Journal of Allergy and Immunology. 2026. doi:10.12932/ap-151025-2164
BibTeX
@article{Geng2026,
author = {Geng, Yulin and Xu, Junmei},
title = {Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2026},
doi = {10.12932/ap-151025-2164}
}
EUVIMED